Research programme: sepsis therapeutics - Hansa Medical

Drug Profile

Research programme: sepsis therapeutics - Hansa Medical

Alternative Names: HM-401; HM-402

Latest Information Update: 09 Dec 2011

Price : $50

At a glance

  • Originator Hansa Medical AB
  • Class Peptides
  • Mechanism of Action Bradykinin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Sepsis

Most Recent Events

  • 09 Dec 2011 Discontinued - Preclinical for Sepsis in Sweden (unspecified route)
  • 19 Feb 2009 Preclinical development is ongoing in Sweden
  • 17 Feb 2006 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top